InternationalUSRemember you can easily switch between MIP US and MIP International at any time

MIP European Life Sciences Forum 2017 - Agenda

June 29, Le Méridien Piccadilly, London





Contact us

Download the brochure here

08:30 Registration

09:00 Opening remarks by James Nurton, managing editor, Managing IP

09:10 Practical planning for Brexit - key risk areas for life sciences companies

  • Parallel imports for pharma products and freedom to operate considerations
  • Trade mark protection – what will happen to existing marks & the future of non-traditional trade marks
  • Cross border injunctions
  • Customs seizures and battling counterfeits

Jeremy Blum, partner, Bristows

10:00 Second medical use patents - can a consensus be reached?

  • Solving practical problems: Warner Lambert v Actavis
  • Practically obtaining and enforcing second medical use patents (validity issues)
  • Examining evolving case law in different jurisdictions
  • Reviewing the issue of 'skinny labelling' with generics

Marianne Schaffner, partner, Dechert
David Cottam, senior director, associate general patent counsel, Teva Europe

10:50 Coffee break and networking

11:20 Supplementary protection certificates: striking the balance to protecting rights

  • Essential updates from key SPCs cases over the past year
  • Combination products judgements
  • Brexit and what this means for SPCs
  • Looking to the future: what should be changed in SPC regulation?

Paul Chapman, head of legal practice, Avidity IP
Jürgen Dressel, head of global patent litigation strategy, Novartis Pharma

12:10 Challenges and regulatory issues with digital health

  • Medical devices and sophisticated diagnostics
  • Government initiatives and legislation to help
  • What trends are we seeing in the landscape to block the launch of new diagnostics?
  • Exploring the role of IoT in digital health solutions: product liability and IP issues

Niklas Mattsson, partner, Awapatent
Anneliese Hassenbuerger
, senior patent attorney, Novartis

13:00 Lunch and networking

13:50 Coordinating UK, EU and US patent strategies: updates from the US

  • The 101 issue: Patent Eligibility in the US - what are the implications for EU patent holders?
  • Inter-partes reviews: challenges and procedural tactics to make your company IPR ready
  • Drawing comparisons between IPRs and revocation actions in Europe

Jennifer Roscetti, partner, Finnegan Henderson Farabow Garrett & Dunner
Erin Sommers, partner, Finnegan Henderson Farabow Garrett & Dunner

 14:40 Unified Patent Court - final preparations for the sunrise period

  • To what extent will the UPC be pro-patentee?
  • Taking steps towards 'troll proofing' your business
  • Alignment of UK courts and other national patent courts within the EU
  • Future forecast: will the UK remain in the system post-Brexit?

Penny Gilbert, partner, Powell Gilbert (moderator)
Francis Tierney, senior patent director, AstraZeneca
Sean Alexander, senior director, European patent counsel, Eli Lilly & Company
Peter Thomsen
, global head IP policy & senior manager IP litigation, Novartis

15:30 Coffee break and networking

15:50 Strategic considerations for dealing with patent portfolios covering biologics

  • Examining the approach of national courts
  • Using declaratory relief to deal with divisional applications
  • Related legal issues that affect the rate of entr y of biosimilars
  • Can UK courts be pragmatic and give commercial solutions? Fujifilm Kyowa Biologics v AbbVie

Luke Kempton, partner, Gowling WLG
Dean Thomas, director IP, Glenmark Pharmaceuticals

16:40 Effective litigation management strategies

  • Annual review and trends of key jurisdictions
  • Coordinating litigation across Europe in life sciences: is there a shift towards harmonisation?
  • Interplay between regulatory regimes and patent litigation

Johan Renes, partner, DLA Piper
Paul Reeskamp
, partner, DLA Piper

17:30 Close of conference




Avidity IP


Dechert LLP


Gowling WLG

Powell Gilbert


Managing IP


ManagingIP profile

John Bochnovic, Executive Director of AIPPI, has resigned from the position (effective April 30, 2018) to return to…

Feb 16 2018 04:19 ·  reply ·  retweet ·  favourite
ManagingIP profile

CAFC says 101 inquiry is a factual determination in “blockbuster” Berkheimer opinion

Feb 16 2018 03:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

US falls to 12th in US Chamber patent ranking Expect to hear this figure mentioned a lot at…

Feb 15 2018 04:45 ·  reply ·  retweet ·  favourite
More from the Managing IP blog

null null null

null null null

February 2018

FRAND aid: Is the European Commission’s SEP guidance useful?

Both patent owners and implementers have welcomed the European Commission’s communication on standard essential patents. Does that mean it has successfully balanced competing interests or merely dodged the difficult questions? James Nurton investigates

Most read articles